Off-label use of azathioprine in dermatology: A systematic review

Archives of Dermatology

Volumn 147, Issue 4, 2011, Pages 474-488

  Schram, Mandy E ^a   Borgonjen, Rinke J ^b   Bik, Cathelijne M J M ^b   Van Der Schroeff, Jan G ^c   Van Everdingen, Jannes J E ^b   Spuls, Phyllis I ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Dutch Society of Dermatology and Venereology   (Netherlands)

^c MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETAMETHASONE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; PLACEBO; PREDNISOLONE; PSORALEN; THIOPURINE METHYLTRANSFERASE;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACTINIC KERATOSIS; ADENOCARCINOMA; ANEMIA; ANEURYSM RUPTURE; ANOREXIA; ARTHRALGIA; ASTHMA; ATOPIC DERMATITIS; BACKACHE; BACTERIAL ARTHRITIS; BREAST CARCINOMA; BRONCHITIS; BULLOUS PEMPHIGOID; CEREBROVASCULAR ACCIDENT; CHOLESTASIS; CONTACT DERMATITIS; DEPRESSION; DERMATOLOGY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; ECZEMA; ENZYME ACTIVITY; EPIDURAL ABSCESS; EPIGASTRIC PAIN; ERYTHEMA MULTIFORME; FATIGUE; FLU LIKE SYNDROME; FOLLICULITIS; FOOT PAIN; GASTROINTESTINAL DISEASE; GINGIVITIS; GRANULOCYTOPENIA; HAND PARESTHESIA; HAY FEVER; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART PALPITATION; HEPATITIS; HERPES LABIALIS; HERPES ZOSTER; HIATUS HERNIA; HIRSUTISM; HUMAN; HYPERGLYCEMIA; IMPETIGO; INFECTION; LEPROSY; LETHARGY; LICHEN PLANUS; LIVER FIBROSIS; LIVER FUNCTION; LIVER TOXICITY; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALAISE; MEGALOBLASTIC ANEMIA; MICROCYTOSIS; MIGRAINE; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; OFF LABEL DRUG USE; OTITIS MEDIA; OUTCOME ASSESSMENT; PANCREATITIS; PANCYTOPENIA; PITYRIASIS RUBRA PILARIS; PRIORITY JOURNAL; PSORIASIS; RESPIRATORY FAILURE; REVIEW; SCLERODERMA; SERUM SICKNESS; SIDE EFFECT; SKIN BRUISING; SKIN CANCER; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; STOMACH PAIN; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOCYTOSIS; TONGUE DISEASE; TREATMENT DURATION; TREMOR; URINARY TRACT INFECTION; URTICARIA; VASCULITIS; VERRUCA VULGARIS; VITILIGO; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; YAWNING;

AZATHIOPRINE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; LEPROSY; MALE; OFF-LABEL USE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN DISEASES;

EID: 79953842364     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.79     Document Type: Review

References (62)

1. Stafford RS. Regulating off-label drug use - rethinking the role of the FDA. N Engl J Med. 2008;358(14):1427-1429. (Pubitemid 351482734)
2. Higgins JPT, Altman DG, eds. Assessing risk of bias in included studies. Section 8.3. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.2Web site. http://www.cochrane-handbook.org/. Accessed February 17, 2011.
3. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-1457.
4. Robinson JK, Dellavalle RP, Bigby M, Callen JP. Systematic reviews: grading recommendations and evidence quality. Arch Dermatol. 2008;144(1):97-99. (Pubitemid 351159395)
5. Ahmed AR, Maize JC, Provost TT. Bullous pemphigoid: clinical and immunologic follow-up after successful therapy. Arch Dermatol. 1977;113(8):1043-1046. (Pubitemid 8163451)
6. Baum J, Hurd E, Lewis D, Ferguson JL, Ziff M. Treatment of psoriatic arthritis with 6-mercaptopurine. Arthritis Rheum. 1973;16(2):139-147.
7. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol. 2007;143(12):1536-1542. (Pubitemid 350277770)
8. Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol. 2002;147(2):324-330.
9. Buckley DA, Baldwin P, Rogers S. The use of azathioprine in severe adult atopic eczema. J Eur Acad Dermatol Venereol. 1998;11(2):137-140. (Pubitemid 28445034)
10. Burton JL, Greaves MW. Azathioprine for pemphigus and pemphigoid - a 4 year follow-up. Br J Dermatol. 1974;91(1):103-109.
11. Burton JL, Harman RM, Peachey RD, Warin RP. A controlled trial of azathioprine in the treatment of pemphigoid [proceedings]. Br J Dermatol. 1978;99(suppl 16):14. (Pubitemid 9007012)
12. Callen JP, af Ekenstam E. Cutaneous leukocytoclastic vasculitis: clinical experience in 44 patients. South Med J. 1987;80(7):848-851.
13. Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine: an effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol. 1991;127(4):515-522.
14. Dethlefs B, Tronnier H. Experiences with antimetabolic therapy in dermatology [in German]. Dermatol Monatsschr. 1973;159(1):34-44.
15. Du Vivier A, Munro DD, Verbov J. Treatment of psoriasis with azathioprine. Br Med J. 1974;1(5897):49-51.
16. Farthing PM, Maragou P, Coates M, Tatnall F, Leigh IM, Williams DM. Characteristics of the oral lesions in patients with cutaneous recurrent erythema multiforme. J Oral Pathol Med. 1995;24(1):9-13.
17. Greaves MW, Dawber R. Azathioprine in psoriasis. Br Med J. 1970;2(5703):237-238.
18. Greaves MW, Burton JL, Marks J, Dawber RPR. Azathioprine in treatment of bullous pemphigoid. Br Med J. 1971;1(5741):144-145.
19. Guillaume J-C, Vaillant L, Bernard P, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol. 1993;129(1):49-53. (Pubitemid 23029669)
20. Heurkens AHM, Westedt ML, Breedveld FC. Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. Arch Intern Med. 1991;151(11):2249-2254.
21. Hewitt J, Escande JP, Leibowitch M, Franceschini P. Trial therapy of psoriasis with azathioprine [in French]. Bull Soc Fr Dermatol Syphiligr. 1970;77(3):392-396.
22. Hon K-LE, Ching GKW, Leung T-F, Chow C-M, Lee KKC, Ng P-C. Efficacy and tolerability at 3 and 6months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults. J Dermatolog Treat. 2009;20(3):141-145.
23. Hughes RC, Collins P, Rogers S. Further experience of using azathioprine in the treatment of severe atopic dermatitis. Clin Exp Dermatol. 2008;33(6):710-711.
24. Hunter GA, Forbes IJ. Treatment of pityriasis rubra pilaris with azathioprine. Br J Dermatol. 1972;87(1):42-45.
25. Jansen GT, Barraza DF, Ballard JL, Honeycutt WM, Dillaha CJ. Generalized scleroderma: treatment with an immunosuppressive agent. Arch Dermatol. 1968;97(6):690-698.
26. Kuanprasert N, Herbert O, Barnetson RS. Clinical improvement and significant reduction of total serum IgE in patients suffering from severe atopic dermatitis treated with oral azathioprine. Australas J Dermatol. 2002;43(2):125-127. (Pubitemid 34533965)
27. Le Quintrec JL, Menkès CJ, Amor B. Severe psoriatic rheumatism: treatment with azathioprine: report of 11 cases [in French]. Rev Rhum Mal Osteoartic. 1990;57(11):815-819.
28. Lear JT, English JSC, Jones P, Smith AG. Retrospective review of the use of azathioprine in severe atopic dermatitis. J Am Acad Dermatol. 1996;35(4):642-643. (Pubitemid 26427080)
29. Leigh IM, Hawk JL. Treatment of chronic actinic dermatitis with azathioprine. Br J Dermatol. 1984;110(6):691-695. (Pubitemid 14084052)
30. Malthieu FG, Guillet G, Larregue M. Azatropin in severe atopic dermatitis: 24 cases [in French]. Ann Dermatol Venereol. 2005;132(2):168-170. (Pubitemid 40380127)
31. Marlowe SNS, Hawksworth RA, Butlin CR, Nicholls PG, Lockwood DNJ. Clinical outcomes in a randomized controlled study comparing azathioprine and prednisolone versus prednisolone alone in the treatment of severe leprosy type 1 reactions in Nepal. Trans R Soc Trop Med Hyg. 2004;98(10):602-609. (Pubitemid 39345161)
32. Meggitt SJ, Reynolds NJ. Azathioprine for atopic dermatitis. Clin Exp Dermatol. 2001;26(5):369-375. (Pubitemid 32863085)
33. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet. 2006;367(9513):839-846. (Pubitemid 43363371)
34. Murphy GM, Maurice PD, Norris PG, Morris RW, Hawk JL. Azathioprine treatment in chronic actinic dermatitis: a double-blind controlled trial with monitoring of exposure to ultraviolet radiation. Br J Dermatol. 1989;121(5):639-646. (Pubitemid 19275252)
35. Murphy L-A, Atherton D. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br J Dermatol. 2002;147(2):308-315.
36. Nadashkevich OD, Davis P, Fritzler M, Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol. 2006;25(2):205-212. (Pubitemid 43372319)
37. Paone CC, Chiarolanza I, Cuomo G, et al. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol. 2007;25(4):613-616. (Pubitemid 47455470)
38. Pearce VJ, Mortimer PS. Hand dermatitis and lymphoedema. Br J Dermatol. 2009; 161(1):177-180.
39. Radmanesh MS, Saedi K. The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatolog Treat. 2006;17(3):151-153. (Pubitemid 44147831)
40. Sharma VK, Chakrabarti A, Mahajan V. Azathioprine in the treatment of Parthenium dermatitis. Int J Dermatol. 1998;37(4):299-302. (Pubitemid 28189695)
41. van Dijk TJ, van Velde JL. Treatment of pemphigus and pemphigoid with azathioprine. Dermatologica. 1973;147(3):179-185.
42. Verma KK, Manchanda Y, Pasricha JS. Azathioprine as a corticosteroid sparing agent for the treatment of dermatitis caused by the weed Parthenium. Acta Derm Venereol. 2000;80(1):31-32. (Pubitemid 30110846)
43. Verma KK, Mittal R, Manchanda Y. Azathioprine for the treatment of severe erosive oral and generalized lichen planus. Acta Derm Venereol. 2001;81(5):378-379. (Pubitemid 34015502)
44. Verma KK, Mahesh R, Srivastava P, Ramam M, Mukhopadhyaya AK. Azathioprine versus betamethasone for the treatment of parthenium dermatitis: a randomized controlled study. Indian J Dermatol Venereol Leprol. 2008;74(5):453-457.
45. Verma KK, Bansal A, Sethuraman G. Parthenium dermatitis treated with azathioprine weekly pulse doses. Indian J Dermatol Venereol Leprol. 2006;72(1):24-27. (Pubitemid 43201336)
46. Weitgasser H. Experiences with an ambulatory immunosuppressive therapy of generalized psoriasis [in German]. Hautarzt. 1972;23(7):316-318.
47. Yap LM, Foley P, Crouch R, Baker C. Chronic actinic dermatitis: a retrospective analysis of 44 cases referred to an Australian photobiology clinic. Australas J Dermatol. 2003;44(4):256-262. (Pubitemid 37518551)
48. Schmitt J, Langan S, Williams HC; European Dermato-Epidemiology Network. What are the best outcome measurements for atopic eczema? a systematic review. J Allergy Clin Immunol. 2007;120(6):1389-1398. (Pubitemid 350216596)
49. Spuls PI, Lecluse LLA, Poulsen M-LNF, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis? quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933-943.
50. Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, Furst DE; OMERACT 6. Current status of outcome measure development for clinical trials in systemic sclerosis: report from OMERACT 6. J Rheumatol. 2003;30(7):1630-1647. (Pubitemid 36835470)
51. Schmitt J, Schäkel K, Schmitt N, Meurer M. Systemic treatment of severe atopic eczema: a systematic review. Acta Derm Venereol. 2007;87(2):100-111. (Pubitemid 46521989)
52. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med. 1985;78(1A):44-49. (Pubitemid 15167365)
53. Taylor AE, Shuster S. Skin cancer after renal transplantation: the causal role of azathioprine. Acta Derm Venereol. 1992;72(2):115-119.
54. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE, Dickson M, Balkwill AM. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet. 1994;343(8908):1249-1252. (Pubitemid 24158045)
55. Sanderson J, Ansari A, Marinaki T, Duley J. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann Clin Biochem. 2004;41(pt 4):294-302.
56. Winter JW, Gaffney D, Shapiro D, et al. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2007;25(9):1069-1077. (Pubitemid 46587697)
57. Nijsten T, Spuls PI, Naldi L, Stern RS. The misperception that clinical trial data reflect long-term drug safety: lessons learned from Efalizumab's withdrawal. Arch Dermatol. 2009;145(9):1037-1039.
58. Schram ME, Spuls PI, Bos JD. Off-label use of efalizumab in dermatology. Exp Rev Dermatol. 2010;5(5):535-547.
59. Lecluse LLA, Naldi L, Stern RS, Spuls PI. National registries of systemic treatment for psoriasis and the European 'Psonet' initiative. Dermatology. 2009;218(4):347-356.
60. Burns T, Breathnach S, Cox N, Griffiths C, eds. Rook's Textbook of Dermatology. 8th ed. Hoboken, NJ: Wiley-Blackwell; 2010.
61. Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. 2nd ed. Amsterdam, the Netherlands: Elsevier Limited; 2008.
62. Wolff K, Katz SI, Goldsmith LA, eds. Fitzpatrick's Dermatology in General Medicine. 7th ed. Berkshire, England: McGraw-Hill Education; 2007.